Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?

被引：0
|
作者：
Kadri Altundag
机构：
[1] MKA Breast Cancer Clinic,
来源：
Breast Cancer Research and Treatment | 2018年 / 167卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：815 / 815
相关论文
共 50 条
  • [31] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
    Rastogi, Priya
    Davidson, Nancy E.
    ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
  • [32] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [33] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer
    Hooge, MNLD
    Perik, PJ
    Gietema, JA
    Jager, PL
    Jonkman, S
    Kosterink, JGW
    Van Veldhuisen, DJJ
    Van der Graaf, WTA
    Sleijfer, DTH
    De Vries, EGE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 210S - 210S
  • [35] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [36] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003
  • [37] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [38] Targeted treatments of HER2-positive metastatic breast cancer: trastuzumab and beyond
    Zardavas, Dimitrios
    Pugliano, Lina
    Ades, Felipe
    Bozovic-Spasojevic, Ivana
    Capelan, Marta
    de Azambuja, Evandro
    BREAST CANCER MANAGEMENT, 2012, 1 (03) : 217 - 233
  • [39] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ
    Procter, M
    Leyland-Jones, B
    Goldhirsch, A
    Untch, M
    Smith, I
    Gianni, L
    Baselga, J
    Bell, R
    Jackisch, C
    Cameron, D
    Dowsett, M
    Barrios, CH
    Steger, G
    Huang, CS
    Andersson, M
    Inbar, M
    Lichinitser, M
    Láng, I
    Nitz, U
    Iwata, H
    Thomssen, C
    Lohrisch, C
    Suter, TM
    Ruschoff, J
    Süto, T
    Greatorex, V
    Ward, C
    Straehle, C
    McFadden, E
    Dolci, MS
    Gelber, RD
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1659 - 1672
  • [40] Neratinib after trastuzumab in patients with HER2-positive breast cancer
    Hasegawa, Takahiro
    Uno, Hajime
    Wei, Lee-Jen
    LANCET ONCOLOGY, 2016, 17 (05): : E176 - E176
12345